Tesamorelin

Tesamorelin (GHRH analogue) is a synthetic GHRH (44 amino acids). The HEIVE catalog describes it as: FDA-approved for HIV-associated lipodystrophy; the only item here with visceral-fat outcomes in registration trials. It is also known as Egrifta.

HEIVE groups Tesamorelin under fat distribution, body recomposition, keeping the result, glycemic control and metabolic health. These catalog categories are not approved indications or evidence that treatment works. See the product-specific regulatory answer below.

Yes, for specific products. Egrifta WR is indicated to reduce excess abdominal fat in adults with HIV-associated lipodystrophy; it is not indicated for general weight-loss management. Approval of a labeled medicine does not approve an arbitrary research or compounded product containing the same ingredient.

• FDA product data (October 6, 2026)
• FDA Egrifta WR label

The HEIVE editorial risk summary for Tesamorelin lists: Joint aches, oedema, injection-site reactions — all documented at trial frequencies. Longer-term concerns: Glucose intolerance in a minority. Monitored with HbA1c in clinical use. This is not a complete or clinically reviewed safety assessment; risks depend on the product, route and population.

Tesamorelin has no single onset time established by this catalog. The editorial timeline starts with “Weeks 1–2”. These are illustrative model or editorial milestones, not clinically validated outcome predictions.

HEIVE's illustrative catalog entry for Tesamorelin: 2 mg subcutaneously once daily. This is not a verified study range or a prescription. A dose cannot be transferred between products, routes or indications; use the specific approved label and the prescribing clinician's instructions where applicable.

The catalog classifies Tesamorelin as having human research. Its paper-count snapshot is not a live PubMed search, a count of controlled human trials or proof of safety. This FAQ has not independently validated the catalog's clinical literature claims.

The source catalog lists only injectable forms for Tesamorelin; it does not establish that every studied or marketed form is injectable.

Preparation of Tesamorelin depends on the exact labeled product. Follow its instructions for formulation, diluent, route and storage. A generic powder recipe must not be applied to a prefilled, ready-to-use or differently formulated product. The catalog's mixing example does not establish sterility or stability.

Storage for Tesamorelin depends on the specific formulation (injectable in the source catalog). Follow the product's labeled temperature, light protection and expiry or discard instructions. A general refrigerator or 28-day rule does not establish stability or sterility for every preparation.

The HEIVE editorial summary for Tesamorelin: Continuous daily dosing is the licensed pattern; no cycling required. This summary is not a clinically validated prediction of tolerance or withdrawal for an individual.

Tesamorelin and Semaglutide share the catalog categories glycemic control, body recomposition and fat distribution. Tesamorelin: FDA-approved for HIV-associated lipodystrophy; the only item here with visceral-fat outcomes in registration trials. Semaglutide: The most rigorously trialled molecule in this library, with cardiovascular outcome data behind it. This is a catalog comparison, not a head-to-head clinical result or a recommendation to substitute treatments.

• View Semaglutide

The HEIVE editorial summary highlights: Cognitive scores improved in older adults in a trial powered for body composition. The cited study, population and formulation must be checked before treating this summary as a clinical finding; this FAQ does not supply a verified research citation for it.